KZR

Kezar Life Sciences, Inc.

Price Chart

No historical data available

Latest Quote

$7.29

Current Price

Open	$7.36
Day High	$7.47
Day Low	$7.27
Volume	616,015

Fetched: 2026-06-25T21:44:50

Stock Information

Shares Outstanding	7.39M
Total Debt	$2.33M
Cash Equivalents	$71.88M
Net Income	$-56.03M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$53.86M
EPS (TTM)	$-6.17
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$-15.81M
Income	$-56.03M
Book/sh	$9.56
Cash/sh	$9.73
Employees	9

Financial Ratios

Quick Ratio	11.23
Current Ratio	11.52
Debt/Eq	3.32

Returns & Margins

ROA	-29.52%
ROE	-59.93%

Ownership

Insider Ownership	15.78%
Institutional Ownership	61.26%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-1.84
P/B	0.76

Analyst Data

Recommendation	none
Target Price	$6.00

Technical Indicators

SMA20	$7.32
SMA50	$7.13
SMA200	$5.81
RSI	51.14
ATR	0.1071

Shares Float	5.16M
Short Float	2.10%
Short Ratio	1.31
Volatility	0.41

Performance History

Week	-1.35%
Month	-1.09%
Quarter	+18.54%
6 Months	+20.50%
YTD	+15.90%
Year	+76.94%
3 Years	-71.96%
5 Years	-87.32%
10 Years	-95.89%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

No history data available. Data will be fetched automatically.

About Kezar Life Sciences, Inc.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

📰 Latest News

Kezar Life Sciences (KZR) Upgraded to Buy: Here's What You Should Know

Zacks • 2026-01-05T17:00:09Z

All You Need to Know About Kezar Life Sciences (KZR) Rating Upgrade to Buy

Zacks • 2025-09-17T16:00:03Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$7,000,000	$0
Operating Revenue	$0	$0	$7,000,000	$0
Expenses
Interest Expense	$1,370,000	$1,593,000	$1,550,000	$1,185,000
Total Expenses	$52,270,000	$89,135,000	$112,237,000	$71,162,000
Other Income Expense	$-6,837,000	$-1,470,000	$-6,187,000	-
Net Non Operating Interest Income Expense	$3,074,000	$6,869,000	$9,554,000	$2,923,000
Interest Expense Non Operating	$1,370,000	$1,593,000	$1,550,000	$1,185,000
Operating Expense	$52,270,000	$89,135,000	$112,237,000	$71,162,000
General And Administrative Expense	$18,514,000	$23,393,000	$26,540,000	$20,153,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-56,033,000	$-83,736,000	$-101,870,000	$-68,239,000
Net Interest Income	$3,074,000	$6,869,000	$9,554,000	$2,923,000
Interest Income	$4,444,000	$8,462,000	$11,104,000	$4,108,000
Normalized Income	$-49,196,000	$-82,266,000	$-95,683,000	$-68,239,000
Net Income From Continuing And Discontinued Operation	$-56,033,000	$-83,736,000	$-101,870,000	$-68,239,000
Total Operating Income As Reported	$-59,107,000	$-90,605,000	$-111,424,000	$-71,162,000
Net Income Common Stockholders	$-56,033,000	$-83,736,000	$-101,870,000	$-68,239,000
Net Income	$-56,033,000	$-83,736,000	$-101,870,000	$-68,239,000
Net Income Including Noncontrolling Interests	$-56,033,000	$-83,736,000	$-101,870,000	$-68,239,000
Net Income Continuous Operations	$-56,033,000	$-83,736,000	$-101,870,000	$-68,239,000
Pretax Income	$-56,033,000	$-83,736,000	$-101,870,000	$-68,239,000
Special Income Charges	$-6,837,000	$-1,470,000	$-6,187,000	$0
Interest Income Non Operating	$4,444,000	$8,462,000	$11,104,000	$4,108,000
Operating Income	$-52,270,000	$-89,135,000	$-105,237,000	$-71,162,000
Per Share
Diluted EPS	$-7.66	$-11.00	$-14.04	$-10.10
Basic EPS	$-7.66	$-11.00	$-14.04	$-10.10
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-46,929,000	$-79,633,000	$-93,067,000	$-66,031,000
Total Unusual Items	$-6,837,000	$-1,470,000	$-6,187,000	$0
Total Unusual Items Excluding Goodwill	$-6,837,000	$-1,470,000	$-6,187,000	$0
Reconciled Depreciation	$897,000	$1,040,000	$1,066,000	$1,023,000
EBITDA (Bullshit earnings)	$-53,766,000	$-81,103,000	$-99,254,000	$-66,031,000
EBIT	$-54,663,000	$-82,143,000	$-100,320,000	$-67,054,000
Diluted Average Shares	$7,316,890	$7,290,245	$7,255,365	$6,736,893
Basic Average Shares	$7,316,890	$7,290,245	$7,255,365	$6,736,893
Diluted NI Availto Com Stockholders	$-56,033,000	$-83,736,000	$-101,870,000	$-68,239,000
Write Off	$1,096,000	$1,549,000	$2,908,000	-
Restructuring And Mergern Acquisition	$5,741,000	$-79,000	$3,279,000	$0
Research And Development	$33,756,000	$65,742,000	$85,697,000	$51,009,000
Selling General And Administration	$18,514,000	$23,393,000	$26,540,000	$20,153,000
Other Gand A	$18,514,000	$23,393,000	$26,540,000	$20,153,000

Fetched: 2026-05-12

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$70,073,000	$116,916,000	$187,570,000	$269,872,000
Total Assets	$76,647,000	$144,682,000	$221,235,000	$299,568,000
Total Non Current Assets	$915,000	$7,194,000	$14,285,000	$13,846,000
Non Current Prepaid Assets	$0	$674,000	$5,461,000	-
Current Assets	$75,732,000	$137,488,000	$206,950,000	$285,722,000
Other Current Assets	$200,000	$351,000	$251,000	$920,000
Assets Held For Sale Current	$520,000	$0	-	-
Prepaid Assets	$1,137,000	$3,954,000	$2,530,000	$9,161,000
Receivables	$1,997,000	$938,000	$2,797,000	-
Other Receivables	$1,813,000	$514,000	$2,102,000	-
Accrued Interest Receivable	$184,000	$424,000	$695,000	-
Cash Cash Equivalents And Short Term Investments	$71,878,000	$132,245,000	$201,372,000	$276,561,000
Cash And Cash Equivalents	$71,878,000	$41,749,000	$35,493,000	$40,456,000
Non Current Accounts Receivable	-	$1,741,000	-	-
Cash Equivalents	-	$41,140,000	$35,349,000	-
Cash Financial	-	$609,000	$144,000	-
Other Non Current Assets	-	-	$134,000	$674,000
Debt
Total Debt	$2,326,000	$16,180,000	$18,933,000	$21,264,000
Long Term Debt And Capital Lease Obligation	$0	$7,437,000	$15,921,000	$18,699,000
Current Debt And Capital Lease Obligation	$2,326,000	$8,743,000	$3,012,000	$2,565,000
Long Term Debt	-	$5,111,000	$10,069,000	$9,834,000
Current Debt	-	$5,217,000	-	-
Other Current Borrowings	-	$5,217,000	-	-
Liabilities
Total Liabilities Net Minority Interest	$6,574,000	$27,766,000	$33,665,000	$29,696,000
Total Non Current Liabilities Net Minority Interest	$0	$7,437,000	$15,921,000	$18,699,000
Current Liabilities	$6,574,000	$20,329,000	$17,744,000	$10,997,000
Payables And Accrued Expenses	$4,182,000	$8,870,000	$11,024,000	$5,172,000
Payables	$507,000	$3,651,000	$8,251,000	$2,479,000
Accounts Payable	$507,000	$3,651,000	$8,251,000	$2,479,000
Other Current Liabilities	-	-	$106,000	$265,000
Equity
Common Stock Equity	$70,073,000	$116,916,000	$187,570,000	$269,872,000
Total Equity Gross Minority Interest	$70,073,000	$116,916,000	$187,570,000	$269,872,000
Stockholders Equity	$70,073,000	$116,916,000	$187,570,000	$269,872,000
Gains Losses Not Affecting Retained Earnings	$0	$-162,000	$-130,000	$-923,000
Retained Earnings	$-490,532,000	$-434,499,000	$-350,763,000	$-248,893,000
Other Equity Adjustments	-	$-162,000	$-130,000	$-923,000
Other
Ordinary Shares Number	$7,331,739	$7,303,629	$7,277,907	$6,849,342
Share Issued	$7,331,739	$7,303,629	$7,277,907	$6,849,342
Tangible Book Value	$70,073,000	$116,916,000	$187,570,000	$269,872,000
Invested Capital	$70,073,000	$127,244,000	$197,639,000	$279,706,000
Working Capital	$69,158,000	$117,159,000	$189,206,000	$274,725,000
Capital Lease Obligations	$2,326,000	$5,852,000	$8,864,000	$11,430,000
Total Capitalization	$70,073,000	$122,027,000	$197,639,000	$279,706,000
Additional Paid In Capital	$560,598,000	$551,570,000	$538,456,000	$519,620,000
Capital Stock	$7,000	$7,000	$7,000	$68,000
Common Stock	$7,000	$7,000	$7,000	$68,000
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$0	$2,326,000	$5,852,000	$8,865,000
Current Capital Lease Obligation	$2,326,000	$3,526,000	$3,012,000	$2,565,000
Pensionand Other Post Retirement Benefit Plans Current	$66,000	$2,716,000	$3,708,000	$3,260,000
Current Accrued Expenses	$3,675,000	$5,219,000	$2,773,000	$2,693,000
Net PPE	$915,000	$4,779,000	$8,690,000	$13,172,000
Accumulated Depreciation	$-3,286,000	$-6,445,000	$-5,420,000	$-4,602,000
Gross PPE	$4,201,000	$11,224,000	$14,110,000	$17,774,000
Leases	$3,268,000	$3,488,000	$3,488,000	$3,366,000
Other Properties	$749,000	$1,886,000	$4,778,000	$9,741,000
Machinery Furniture Equipment	$184,000	$5,850,000	$5,844,000	$4,667,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$0	$90,496,000	$165,879,000	$236,105,000

Fetched: 2026-05-12

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-51,785,000	$-74,241,000	$-83,455,000	$-60,424,000
Operating Activities
Operating Cash Flow	$-51,777,000	$-74,212,000	$-81,645,000	$-58,846,000
Cash Flow From Continuing Operating Activities	$-51,777,000	$-74,212,000	$-81,645,000	$-58,846,000
Operating Gains Losses	$428,000	-	-	$12,000
Investing Activities
Capital Expenditure	$-8,000	$-29,000	$-1,810,000	$-1,578,000
Investing Cash Flow	$92,463,000	$80,428,000	$76,046,000	$-91,392,000
Cash Flow From Continuing Investing Activities	$92,463,000	$80,428,000	$76,046,000	$-91,392,000
Financing Activities
Issuance Of Capital Stock	$65,000	$103,000	$638,000	$126,542,000
Financing Cash Flow	$-10,585,000	$103,000	$638,000	$127,861,000
Cash Flow From Continuing Financing Activities	$-10,585,000	$103,000	$638,000	$127,861,000
Net Common Stock Issuance	$65,000	$103,000	$638,000	$126,542,000
Common Stock Issuance	$65,000	$103,000	$638,000	$126,542,000
Other
Repayment Of Debt	$-10,650,000	$0	$0	-
Interest Paid Supplemental Data	$766,000	$1,335,000	$1,315,000	$973,000
End Cash Position	$71,878,000	$41,749,000	$35,493,000	$40,456,000
Beginning Cash Position	$41,749,000	$35,493,000	$40,456,000	$62,882,000
Effect Of Exchange Rate Changes	$28,000	$-63,000	$-2,000	$-49,000
Changes In Cash	$30,101,000	$6,319,000	$-4,961,000	$-22,377,000
Net Issuance Payments Of Debt	$-10,650,000	$0	$0	$0
Net Long Term Debt Issuance	$-10,650,000	$0	$0	$0
Long Term Debt Payments	$-10,650,000	$0	$0	-
Net Investment Purchase And Sale	$92,350,000	$80,457,000	$77,851,000	$-89,814,000
Sale Of Investment	$134,981,000	$171,794,000	$258,250,000	$242,389,000
Purchase Of Investment	$-42,631,000	$-91,337,000	$-180,399,000	$-332,203,000
Net PPE Purchase And Sale	$113,000	$-29,000	$-1,805,000	$-1,578,000
Sale Of PPE	$121,000	$0	$5,000	$0
Purchase Of PPE	$-8,000	$-29,000	$-1,810,000	$-1,578,000
Change In Working Capital	$-5,403,000	$-1,300,000	$4,706,000	$-4,459,000
Change In Other Working Capital	$-2,389,000	$-1,669,000	$-303,000	$-94,000
Change In Other Current Assets	$2,415,000	$3,180,000	$-4,921,000	$-392,000
Change In Payables And Accrued Expense	$-7,338,000	$-3,146,000	$6,347,000	$1,814,000
Change In Prepaid Assets	$1,909,000	$335,000	$3,583,000	$-5,787,000
Other Non Cash Items	$466,000	$267,000	$238,000	$224,000
Stock Based Compensation	$8,963,000	$13,011,000	$18,137,000	$14,006,000
Asset Impairment Charge	$907,000	$1,549,000	$2,908,000	$0
Amortization Of Securities	$-2,002,000	$-5,043,000	$-6,830,000	$-1,401,000
Depreciation Amortization Depletion	$897,000	$1,040,000	$1,066,000	$1,023,000
Depreciation And Amortization	$897,000	$1,040,000	$1,066,000	$1,023,000
Net Foreign Currency Exchange Gain Loss	$282,000	$0	$0	-
Net Income From Continuing Operations	$-56,033,000	$-83,736,000	$-101,870,000	$-68,239,000
Proceeds From Stock Option Exercised	-	$103,000	$638,000	$1,319,000
Issuance Of Debt	-	-	$0	$0
Long Term Debt Issuance	-	-	$0	$0
Change In Other Current Liabilities	-	-	-	$-94,000
Gain Loss On Sale Of PPE	-	-	-	$12,000

Fetched: 2026-05-12